Micah Steffek

Micah Steffek

Auto-generated profile, based on publicly available information

Micah Steffek

Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA 94080, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2020 in Science
Verified
Journal Article
Closed access
PDF file
LRLionel Rougé
Lionel Rougé
NCNancy Chiang
Nancy Chiang
MSMicah Steffek
Micah Steffek
CKChristine Kugel
Christine Kugel
TCTristan I. Croll
Tristan I. Croll
ARAlexis Rohou
Alexis Rohou
Clustering for the kill: Cluster of differentiation 20 (CD20) is a membrane protein that defines most B cell populations and is the target of therapeutic antibodies to treat malignancies and autoimmune disorders. Rougé et al. present the structure of CD20 bound to the antibody rituximab that activates the complement system to kill B cells. CD20 forms a dimer and each monomer binds one rituximab antigen-binding fragment (Fab) to give 2:2 stoichiometry. The compact packing between Fab arms and CD20 gives rise to circular assemblies with a diameter similar to that of antibody hexamers known to recruit the first component of the complement cascade. Science , this issue p. 1224

17 May 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JQJohn G. Quinn
John G. Quinn
KPKeith E. Pitts
Keith E. Pitts
MSMicah Steffek
Micah Steffek
MMMelinda M. Mulvihill
Melinda M. Mulvihill

9 October 2025 in bioRxiv
Verified
Preprint
Open access
JGJing Guo
Jing Guo
TBTomas P. Bachor
Tomas P. Bachor
RTRyan Takahashi
Ryan Takahashi
MSMicah Steffek
Micah Steffek
GFGabriel A. Fitzgerald
Gabriel A. Fitzgerald
EYErnie Yulyaningsih
Ernie Yulyaningsih
The NLRP3 inflammasome is a key mediator of innate immunity that integrates inflammatory and metabolic stress signals. Increased and/or chronic activation of this critical pathway has been implicated in obesity, with hypothalamic neuroinflammation linked to dysregulation of energy balance. TN-783 is an investigational, CNS-penetrant, small-molecule NLRP3 inhibitor that potently suppressed inflammasome activation across multiple in vitro assays. In diet-induced obese (DIO) mice, only TN-783, and not the peripherally restricted NLRP3 inhibitor TN-101, produced progressive and sustained weight loss, underscoring the requirement for central target engagement. Weight loss was driven by a persistent reduction in food intake across both acute and chronic phases, without altering energy expenditure. This effect was further characterized by selective reduction of fat mass, with minimal impact on lean tissues. Mechanistically, NLRP3 inhibition attenuated DIO-induced hypothalamic neuroinflammation and partially reversed obesity-associated molecular changes based on transcriptomic and proteomic profiling of the hypothalamus. Beyond monotherapy, TN-783 enhanced the effects of the GLP-1 receptor agonist semaglutide by amplifying weight loss, reinitiating weight loss after semaglutide effect had plateaued, and maintaining the weight loss benefit after semaglutide withdrawal. Discontinuation of TN-783 resulted in reversal of both weight and feeding effects, indicating that its therapeutic activity requires ongoing target engagement rather than permanent remodeling of metabolic pathways. Collectively, these observations support central NLRP3 inhibition as a distinct and promising approach for obesity treatment, offering robust induction and sustained maintenance of weight loss while preserving reversibility.